Biagio Ricciuti
Onco
Daily
Facebook
RSS
X
Youtube
Linkedin
September, 2024
September 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
« Aug
Biagio Ricciuti
Sep 13, 2024, 14:12 |
Blog
Xiuning Le: BAY88 in pre-treated HER2-mut NSCLC
Xiuning Le shared a post by Biagio Ricciuti, on X, adding: "BAY88 in pre-treated HER2-mut…
Sep 11, 2024, 01:59 |
Societies
38 Posts Not to Miss From WCLC24 Day 3!
The WCLC24 is taking place at the San Diego Convention Center from September 7 to…
Sep 6, 2024, 13:28 |
Insight
Biagio Ricciuti: How adaptive mechanisms and increased GTP loading confer resistance to KRAS G12C OFF
Biagio Ricciuti shared on X: “Our in Nature Communications our collaborative effort showing how adaptive mechanisms…
Aug 27, 2024, 23:18 |
Insight
Explore the current therapeutic landscape for Lung Cancer with Biagio Ricciuti at the upcoming ILCS24
International Lung Cancer Summit (ILCS) shared on X: “What is the current therapeutic landscape for Lung…
Aug 18, 2024, 06:12 |
Blog
Biagio Ricciuti: KEAPness signature outperforms deleterious KEAP1 mutations in predicting ICI efficacy in NSCLC
Biagio Ricciuti shared on X: "Sharing our latest effort out in Clinical Cancer Research! This multicenter…
Aug 16, 2024, 14:13 |
Insight
OS rates for IMpower133 and IMbrella A extension study in SCLC
Biagio Ricciuti shared a paper by Martin Reck et al. on X, adding: “Five-year survival…
Aug 12, 2024, 06:16 |
Insight
Biagio Ricciuti: In vivo vulnerabilities to GPX4 and HDAC inhibitors in BRAF V600E lung adenocarcinoma
Biagio Ricciuti shared a post on LinkedIn about his recent paper, commenting: “Our collaborative effort…
Aug 12, 2024, 02:37 |
Blog
Biagio Ricciuti: Vulnerabilities to GPX4 and HDAC inhibitors in BRAF V600E lung adenocarcinoma
Biagio Ricciuti posted on X about recent paper by Marie-Julie Nokin et al., titled "In…
Aug 9, 2024, 12:23 |
Blog
The 6th International Lung Cancer Summit
The 6th International Lung Cancer Summit is a hybrid conference that will be held at…
Aug 7, 2024, 20:03 |
Insight
Recurrence of Non–Small Cell Lung Cancer With Visceral Pleural Invasion summarized by Biagio Ricciuti
Biagio Ricciuti shared a post on X: "Recurrence of Non–Small Cell Lung Cancer With Visceral…
Aug 6, 2024, 06:07 |
Insight
Primary analysis of the phase 2 INSIGHT 2 study of tepotinib combined with osimertinib
Lungevity Foundation shared a recent article by Yi-Long Wu, commenting: "What's after osimertinib for pts…
Jul 31, 2024, 09:17 |
Blog
New Lung Cancer Considered episode, the use of ICIs in the treatment of molecular driven NSCLC
IASLC shared on X: "In this Lung Cancer Considered episode, Narjust Florez and 2 esteemed…
Jul 30, 2024, 01:45 |
Insight
TKIs with vs without upfront SRS for EGFR+ and ALK+ NSCLC and brain metastasis
Biagio Ricciuti shared on X about a recent paper by Luke Pike et al. titled…
Jul 21, 2024, 20:02 |
Blog
Biagio Ricciuti: Join us in Lausanne for the 2024 International Lung Cancer Summit
Biagio Ricciuti shared a post on X by the International Lung Cancer Summit, adding: "Join…
Jul 14, 2024, 06:26 |
Insight
Daniele Marinelli: NRF2-driven transcription in NSCLC
Daniele Marinelli, PhD student at the Sapienza University of Rome, shared a post on X…
Jul 12, 2024, 23:29 |
Insight
Clinical Utility of Pre-surgical ctDNA Detection in Early Stage NSCLC
Biagio Ricciuti shared on X: "Clinical Utility of Pre-surgical ctDNA Detection in Early Stage NSCLC…
Jul 10, 2024, 02:17 |
Blog
Biagio Ricciuti: Resistance mechanisms in insertion-mutant NSCLC
Biagio Ricciuti shared on X: "Resistance mechanisms to EGFR TKIs in EGFR ex 20 insertion-mutant NSCLC:…
Jul 9, 2024, 07:10 |
Insight
10 Papers Suggested By Wafik S. El-Deiry on July 9
Wafik S. El-Deiry, Director of the Legorreta Cancer Center of Brown University and Associate Dean for…
Jul 1, 2024, 02:31 |
Blog
Biagio Ricciuti receives a 2024 IASLC YIA to develop new therapies for KRAS amplified NSCLC
Biagio Ricciuti shared a post by Dana-Farber News, on X: "Thrilled to receive a 2024…
Jun 28, 2024, 04:59 |
Blog
Mihaela Aldea received a 2024 IASLC YIA
Mihaela Aldea, Medical Oncologist at the Gustave Roussy, shared a post on X: "Honored to…
Jun 27, 2024, 20:12 |
Blog
Dana-Farber News - Biagio Ricciuti receives IASLC 2024 Young Investigator Grant
Dana-Farber News shared on X: "Congratulations to Biagio Ricciuti, who is a recipient of the IASLC…
Jun 21, 2024, 04:15 |
Insight
Biagio Ricciuti: Fusion partners and chromosomal breakpoints of oncogenic fusions are not stochastic
Giannis Mountzios, Medical Oncologist at the Department of Medical Oncology in the Air Force General…
Jun 20, 2024, 12:07 |
Insight
Research into why some respond to TKIs better than others - Oncogene Cancer Research
Oncogene Cancer Research recently shared a post on X: "Worth reading this deep dive into…
May 31, 2024, 02:35 |
Blog
Biagio Ricciuti: Great conversation on the role of ICI in patients with NSCLC and driver mutations
Biagio Ricciuti shared a post by Narjust Florez on X, adding: , "I had a…
May 29, 2024, 09:25 |
Insight
Biagio Ricciuti: The association of automatically extracted body composition metrics with IO efficacy in mNSCLC
Biagio Ricciuti, recently posted on X: "Out in JAMA Oncology! Our effort to determine the…
May 12, 2024, 13:30 |
Blog
Biagio Ricciuti: Insightful discussions at Rome Lung 24
Biagio Ricciuti shared a post by Stephen Liu on X and added: "Had a great…
May 11, 2024, 12:13 |
Insight
Biagio Ricciuti: Comprehensive mutational scanning of EGFR reveals TKI sensitivities of extracellular domain mutants
Biagio Ricciuti, Medical Oncologist at Dana-Farber Cancer Institute, shared on X/Twitter: "Comprehensive mutational scanning of EGFR…
Apr 26, 2024, 10:00 |
Insight
Biagio Ricciuti: Our work on long-term outcomes to PD-1 monotherapy by increasing PD-L1 levels in NSCLC is out in JTO and JTO CRR
Biagio Ricciuti, Medical Oncologist at Dana-Farber Cancer Institute, shared on X/Twitter: ''Our work on long-term…
Apr 9, 2024, 13:33 |
Blog
Biagio Ricciuti: If you are at AACR24, stop by poster 21 (section 1) to learn more about the discovery of ALK-specific TCR clonotypes
Biagio Ricciuti, Medical Oncologist at Dana-Farber Cancer Institute, shared on X/Twitter: ''If you are at…
Apr 8, 2024, 23:10 |
Blog
Biagio Ricciuti: MET kinase domain mutations as novel and targetable alterations in NSCLC
Biagio Ricciuti, Medical oncologist at Dana-Farber Cancer Institute, shared a post on LinkedIn: "Our collaborative effort…
Apr 8, 2024, 14:35 |
Insight
Biagio Ricciuti: Our collaborative effort to characterize MET kinase domain mutations as novel and targetable alterations in NSCLC and other cancer types
Biagio Ricciuti, Medical Oncologist at Dana-Farber Cancer Institute, posted on X: "Our collaborative effort to…
Apr 7, 2024, 23:28 |
Insight
Biagio Ricciuti: MET kinase domain mutations as novel & targetable alterations in NSCLC and other cancer types
Biagio Ricciuti, Medical Oncologist at Dana-Farber Cancer Institute, shared on X: "Our collaborative effort to…
Jan 18, 2024, 15:55 |
Blog
Biagio Ricciuti: Mechanisms of acquired resistance to PD-(L)1 blockade in NSCLC
Biagio Ricciuti, Medical Oncologist at Dana-Farber Cancer Institute, shared on LinkedIn: “Now out in the…
All:
33
Posts:
1 - 100
OncoDaily Forms Strategic Partnership with the National Foundation for Cancer Research (NFCR)
Hugh Jackman and Skin Cancer: How He Went Against, How He Survived, and More
100 Influential Women in Oncology: Key Opinion Leaders to Follow on Social Media in 2024: Part 4
34 Posts Not to Miss From ESMO24 Day 4
40 Posts Not To Miss From ESMO24 Day 3
Special Coverage
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Facebook
RSS Feed
X
Linkedin
Youtube